Drug Profile
MEDI 565
Alternative Names: AMG-211; CEA BiTE mAb; MEDI-565; MT-111Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Micromet Inc
- Developer Amgen; MedImmune; University Medical Center Groningen
- Class Antineoplastics; Bispecific antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Gastrointestinal cancer; Solid tumours
Most Recent Events
- 05 Feb 2019 CTP push274228: kdm updated, HE created, not reviewed the profile
- 25 Jan 2019 University Medical Center Groningen and Amgen discontinued a phase I/II PET imaging trial for Gastrointestinal cancer (Late-stage disease, Second-line therapy or greater) in Netherlands (IV), prior to January 2019 (EudraCT2015-004370-14)
- 19 Oct 2018 Safety, pharmacokinetics and immunogenecity data from a phase I study in Gastrointestinal cancer presented at the 43rd European Society for Medical Oncology Congress (ESMO-2018)